Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3942702rdf:typepubmed:Citationlld:pubmed
pubmed-article:3942702lifeskim:mentionsumls-concept:C0043210lld:lifeskim
pubmed-article:3942702lifeskim:mentionsumls-concept:C0042149lld:lifeskim
pubmed-article:3942702lifeskim:mentionsumls-concept:C1705480lld:lifeskim
pubmed-article:3942702lifeskim:mentionsumls-concept:C0042418lld:lifeskim
pubmed-article:3942702lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:3942702lifeskim:mentionsumls-concept:C1948023lld:lifeskim
pubmed-article:3942702lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:3942702pubmed:issue1lld:pubmed
pubmed-article:3942702pubmed:dateCreated1986-3-21lld:pubmed
pubmed-article:3942702pubmed:abstractTextThree analogues of posterior pituitary hormones, 1-deamino-2-D-Tyr(OEt)-4-Val-8-Orn-vasotocin(dE-VVT), 1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn-vasotocin(dE-TVT) and 1-deamino-2-D-Tyr(OEt)-oxytocin(dE-OXY) were compared for their inhibitory effects on vasopressin (VP)-induced uterine activity in healthy women. At menstruation, during recording of intrauterine pressure (18 recording sessions in 11 women), intravenous infusion of lysine vasopressin (LVP, 1 ng/min/kg/body weight) induced an increase of the uterine activity and dysmenorrhoea-like symptoms. Intravenous injections of all analogues (10 micrograms/kg body weight) caused relief of symptoms and inhibition of uterine activity, dE-TVT was the most effective and dE-OXY was least active. With dE-TVT almost complete inhibition of contractions was seen during the first 10 min after injection. The duration of effect was also greatest with that analogue (40-50 min). Only dE-OXY had an agonist effect on spontaneous uterine activity. Pharmacokinetic studies of intravenous dE-TVT (10 ng/kg body weight) showed that the plasma half-life was approximately 16 min and the clearance 30 l/h. The bioavailability of 100 ng/kg given intranasally was about 5.5%. Further studies are recommended.lld:pubmed
pubmed-article:3942702pubmed:languageenglld:pubmed
pubmed-article:3942702pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3942702pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3942702pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3942702pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3942702pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3942702pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3942702pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3942702pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3942702pubmed:statusMEDLINElld:pubmed
pubmed-article:3942702pubmed:monthJanlld:pubmed
pubmed-article:3942702pubmed:issn0306-5456lld:pubmed
pubmed-article:3942702pubmed:authorpubmed-author:MelinPPlld:pubmed
pubmed-article:3942702pubmed:authorpubmed-author:AkerlundMMlld:pubmed
pubmed-article:3942702pubmed:authorpubmed-author:LundinSSlld:pubmed
pubmed-article:3942702pubmed:authorpubmed-author:TrojnarJJlld:pubmed
pubmed-article:3942702pubmed:authorpubmed-author:HaukssonAAlld:pubmed
pubmed-article:3942702pubmed:issnTypePrintlld:pubmed
pubmed-article:3942702pubmed:volume93lld:pubmed
pubmed-article:3942702pubmed:ownerNLMlld:pubmed
pubmed-article:3942702pubmed:authorsCompleteYlld:pubmed
pubmed-article:3942702pubmed:pagination22-7lld:pubmed
pubmed-article:3942702pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:meshHeadingpubmed-meshheading:3942702-...lld:pubmed
pubmed-article:3942702pubmed:year1986lld:pubmed
pubmed-article:3942702pubmed:articleTitleVasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women.lld:pubmed
pubmed-article:3942702pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3942702pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3942702pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed